Moreover, STAT5 has been shown to play a key role in the maintenance of LSCs from CML patients, whereas combining IM with a STAT5 inhibitor triggers the death of CML LSCs.21 The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.